BACKGROUND/AIMS: HIV and hepatitis C virus (HCV) share common modes of transmission, resulting in about 33% incidence of coinfection among people infected with HIV. The survival benefit from highly effective antiretroviral therapy (HAART) for HIV infection is resulting in an increased incidence of hepatocellular carcinoma (HCC) in this population. There are no reports to date regarding the coadministration of HAART and sorafenib for hepatocellular carcinoma. METHODS: We report the case of a 42-year-old male patient coinfected with HIV and HCV who developed advanced HCC not amenable to curative therapy. The patient was treated with sorafenib, an oral multikinase inhibitor shown to lead to a longer median survival time and time to progression in patients with advanced HCC. Antiretroviral therapy was continued during sorafenib therapy. RESULTS: The patient achieved a partial tumor response after 3 months and continued to respond at subsequent assessments. His serum alpha-fetoprotein normalized from 2,172 IU/ml to 2 IU/ml. He had durable stable disease after 23 months of therapy. Antiretroviral therapy was efficacious (CD4(+) lymphocyte count, 377/microl; HIV viremia, <50 copies/ml). The simultaneous administration of these therapies was well tolerated. No grade 3 or 4 toxicities were observed. Exacerbation of pre-existing hypertension, grade 2 diarrhea, and grade 1 skin reaction were observed. CONCLUSIONS: This is the first report in which sorafenib has been successfully used to treat HCC in a patient with HIV-HCV coinfection.
BACKGROUND/AIMS: HIV and hepatitis C virus (HCV) share common modes of transmission, resulting in about 33% incidence of coinfection among people infected with HIV. The survival benefit from highly effective antiretroviral therapy (HAART) for HIV infection is resulting in an increased incidence of hepatocellular carcinoma (HCC) in this population. There are no reports to date regarding the coadministration of HAART and sorafenib for hepatocellular carcinoma. METHODS: We report the case of a 42-year-old male patient coinfected with HIV and HCV who developed advanced HCC not amenable to curative therapy. The patient was treated with sorafenib, an oral multikinase inhibitor shown to lead to a longer median survival time and time to progression in patients with advanced HCC. Antiretroviral therapy was continued during sorafenib therapy. RESULTS: The patient achieved a partial tumor response after 3 months and continued to respond at subsequent assessments. His serum alpha-fetoprotein normalized from 2,172 IU/ml to 2 IU/ml. He had durable stable disease after 23 months of therapy. Antiretroviral therapy was efficacious (CD4(+) lymphocyte count, 377/microl; HIV viremia, <50 copies/ml). The simultaneous administration of these therapies was well tolerated. No grade 3 or 4 toxicities were observed. Exacerbation of pre-existing hypertension, grade 2 diarrhea, and grade 1 skin reaction were observed. CONCLUSIONS: This is the first report in which sorafenib has been successfully used to treat HCC in a patient with HIV-HCV coinfection.
Authors: Javier Murillas; Manuel Del Río; Melchor Riera; Pedro Vaquer; Ana Salas; María Leyes; M Angeles Ribas; María Peñaranda Vera; Concepcion Villalonga Journal: Eur J Intern Med Date: 2005-04 Impact factor: 4.487
Authors: B Soto; A Sánchez-Quijano; L Rodrigo; J A del Olmo; M García-Bengoechea; J Hernández-Quero; C Rey; M A Abad; M Rodríguez; M Sales Gilabert; F González; P Mirón; A Caruz; F Relimpio; R Torronteras; M Leal; E Lissen Journal: J Hepatol Date: 1997-01 Impact factor: 25.083
Authors: M E Roland; B Barin; L Carlson; L A Frassetto; N A Terrault; R Hirose; C E Freise; L Z Benet; N L Ascher; J P Roberts; B Murphy; M J Keller; K M Olthoff; E A Blumberg; K L Brayman; S T Bartlett; C E Davis; J M McCune; B M Bredt; D M Stablein; P G Stock Journal: Am J Transplant Date: 2007-12-18 Impact factor: 8.086
Authors: Gary M Clifford; Martin Rickenbach; Jerry Polesel; Luigino Dal Maso; Ingrid Steffen; Bruno Ledergerber; Andri Rauch; Nicole M Probst-Hensch; Christine Bouchardy; Fabio Levi; Silvia Franceschi Journal: AIDS Date: 2008-10-18 Impact factor: 4.177
Authors: Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix Journal: N Engl J Med Date: 2008-07-24 Impact factor: 91.245
Authors: Thomas S Uldrick; Priscila H Gonçalves; Kathleen M Wyvill; Cody J Peer; Wendy Bernstein; Karen Aleman; Mark N Polizzotto; David Venzon; Seth M Steinberg; Vickie Marshall; Denise Whitby; Richard F Little; John J Wright; Michelle A Rudek; William D Figg; Robert Yarchoan Journal: Oncologist Date: 2017-03-24